Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Retained Earnings: ¥-1,640 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688266 Suzhou Zelgen Biopharmaceuticals Co Ltd SHSE:688266
70 GF Score
Price ¥117.99
GF Value ¥222.27
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Suzhou Zelgen Biopharmaceuticals Co Retained Earnings?

Suzhou Zelgen Biopharmaceuticals Co SHSE:688266 +0.53% 70 Retained Earnings is ¥-1,640 Mil as of Jun. 2026. GuruFocus rates SHSE:688266 with a GF Score™ of 70/100 and a GF Value™ of ¥222.27 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Suzhou Zelgen Biopharmaceuticals Co's retained earnings for the quarter that ended in Jun. 2026 was ¥-1,640 Mil.

Suzhou Zelgen Biopharmaceuticals Co's quarterly retained earnings increased from Dec. 2025 (¥-2,280 Mil) to Mar. 2026 (¥-1,647 Mil) and increased from Mar. 2026 (¥-1,647 Mil) to Jun. 2026 (¥-1,640 Mil).

Suzhou Zelgen Biopharmaceuticals Co's annual retained earnings declined from Dec. 2023 (¥-1,979 Mil) to Dec. 2024 (¥-2,117 Mil) and declined from Dec. 2024 (¥-2,117 Mil) to Dec. 2025 (¥-2,280 Mil).


Suzhou Zelgen Biopharmaceuticals Co  (SHSE:688266) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Suzhou Zelgen Biopharmaceuticals Co Retained Earnings Historical Data

* Premium members only.

The historical data trend for Suzhou Zelgen Biopharmaceuticals Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suzhou Zelgen Biopharmaceuticals Co Retained Earnings Chart

Suzhou Zelgen Biopharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,242.56 -1,700.33 -1,978.91 -2,116.74 -2,279.69

Suzhou Zelgen Biopharmaceuticals Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,189.55 -2,210.16 -2,279.69 -1,647.08 -1,639.68
SHSE:688266
70GF Score
Suzhou Zelgen Biopharmaceuticals Co Ltd SHSE:688266
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Suzhou Zelgen Biopharmaceuticals Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of ¥-1,640 Mil mean?
Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) has a Retained Earnings of ¥-1,640 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors.
Is Suzhou Zelgen Biopharmaceuticals Co's Retained Earnings too high?
Suzhou Zelgen Biopharmaceuticals Co's current Retained Earnings is ¥-1,640 Mil. Overall, Suzhou Zelgen Biopharmaceuticals Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Zelgen Biopharmaceuticals Co's Retained Earnings compare to VRTX and REGN?
Suzhou Zelgen Biopharmaceuticals Co's Retained Earnings of ¥-1,640 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. Suzhou Zelgen Biopharmaceuticals Co's current Retained Earnings is ¥-1,640 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Zelgen Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥222.27, compared to a current price of ¥117.99 — trading 46.9% below its estimated fair value. The current Retained Earnings is ¥-1,640 Mil. Suzhou Zelgen Biopharmaceuticals Co's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266), the current Retained Earnings is ¥-1,640 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Overvalued in 2026?

Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co stock appears to be undervalued. The current stock price of ¥117.99 is trading 46.9% below its estimated GF Value™ of ¥222.27. GuruFocus considers Suzhou Zelgen Biopharmaceuticals Co to be Significantly Undervalued.

Key valuation signals for SHSE:688266:

  • Retained Earnings: ¥-1,640 Mil
  • GF Value™: ¥222.27 vs. price of ¥117.99 (46.9% below fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the SHSE:688266 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Suzhou Zelgen Biopharmaceuticals Co Business Description

Address No.209 Chenfeng Road, Yushan Town, Jiangsu Province, Kunshan, CHN
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
70GF Score

Get the complete analysis for SHSE:688266

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥117.99
Price
¥222.27
GF Value